Home » USA Broker Ratings » Neurocrine Biosciences, Inc. – Consenus Indicates Potential 17.0% Upside

Neurocrine Biosciences, Inc. – Consenus Indicates Potential 17.0% Upside

Neurocrine Biosciences, Inc. with ticker code (NBIX) now have 18 analysts covering the stock with the consensus suggesting a rating of ‘Buy’. The target price ranges between 130 and 93 with a mean TP of 111.33. Now with the previous closing price of 95.18 this is indicating there is a potential upside of 17.0%. The 50 day moving average now sits at 95.53 and the 200 day moving average is 86. The company has a market capitalisation of $8,738m. Find out more information at: http://www.neurocrine.com

Neurocrine Biosciences, Inc. discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company offers INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor (VMAT2), which is used for the treatment of movement disorders; ORILISSA, a gonadotropin-releasing hormone (GnRH) antagonist for use in women’s health. Its product candidates in clinical development include elagolix that is in Phase III clinical trial for Uterine Fibroids; opicapone, a catechol-O-methyltransferase inhibitor, which is in Phase III clinical trial that is used for in adjunct therapy and preparations of levodopa/DOPA decarboxylase inhibitors for adult patients with Parkinson’s disease; and NBI-74788, which is in Phase II clinical trial for the treatment of congenital adrenal hyperplasia. The company’s product candidates also comprise VMAT2 Inhibitors and which are in Phase I clinical trial for neurology/psychiatry disorders. It has collaborations and agreements with AbbVie Inc. to develop and commercialize elagolix and GnRH antagonists for women’s and men’s health; Mitsubishi Tanabe Pharma Corporation to develop and commercialize INGREZZA for movement disorders; and BIAL – Portela & Ca, S.A. to develop and commercialize opicapone for the treatment of human diseases and conditions, including Parkinson’s disease. The company also has a research collaboration agreement with Jnana Therapeutics Inc. to discover novel small molecule therapeutics for multiple targets for central nervous system disorders; and a collaboration and license agreement with Voyager Therapeutics, Inc. for the research, development, and commercialization of VY-AADC program for Parkinson’s disease and VY-FXN01 program for Friedreich’s ataxia. Neurocrine Biosciences, Inc. was founded in 1992 and is headquartered in San Diego, California.